Former Chief Financial Officer · GYRE THERAPEUTICS, INC. (GYRE)

Fletcher Payne

A named executive officer of GYRE THERAPEUTICS in every fiscal year CompBrief holds from FY2017 to FY2019. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2019

$471,208

Salary $252,800Stock awards $0

FY2018: $969,476

3rd of 3 named executive officers at Gyre Therapeutics by FY2019 total.

3 named officers on file for GYRE THERAPEUTICS, FY2019

Fletcher Payne’s pay file — $29

  • 3 fiscal years of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how GYRE THERAPEUTICS’s whole pay program stands against its peers

  • GYRE THERAPEUTICS’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on GYRE→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed May 1, 2020 (DEF 14A).

Free

Get Fletcher Payne’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Fletcher Payne compensation by year

GYRE THERAPEUTICS Summary Compensation Table · all 3 fiscal years held
In US dollars, as GYRE THERAPEUTICS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2017FY2018FY2019
Salary$335,244$345,301$252,800
Bonus$152,536$120,855$0
Stock awards$0$0$0
Option awards$289,351$501,228$216,361
Non-equity incentive$0$0$0
Pension and deferred compensation$0$0$0
All other$2,092$2,092$2,047
Total$779,223$969,476$471,208

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: GYRE THERAPEUTICS, INC. DEF 14A filed May 1, 2020, accession 0001564590-20-020531, and prior-year filings. Open the filing on EDGAR.

How this page was built: the GYRE THERAPEUTICS, INC. filed document, accession 0001564590-20-020531. Every figure is read from that document and cited to the page and table it appears in. Filed May 1, 2020.

$779K
$969K
$471K
FY17
FY18
FY19
SalaryBonusOption awardsAll other

GYRE THERAPEUTICS’s named executive officers, FY2019

as the company reported each
Named executive officerRoleFY2019 total
Nassim UsmanPresident and Chief Executive Officer$1,198,865
M.B.B.Ch. Howard LevyChief Medical Officer$733,018
Fletcher Payne · this pageFormer Chief Financial Officer$471,208

The full GYRE THERAPEUTICS compensation record

free company brief

This page is one person within GYRE THERAPEUTICS's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are GYRE THERAPEUTICS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Fletcher Payne's compensation dossier · One-time report. No refunds.